相似文献
1
Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes.
Drug Discov Today. 2018 Sep;23(9):1635-1643. doi: 10.1016/j.drudis.2018.04.010. Epub 2018 Apr 23.
2
Long non-coding RNAs: A view to kill ovarian cancer.
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188584. doi: 10.1016/j.bbcan.2021.188584. Epub 2021 Jun 19.
3
Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer.
Cell Physiol Biochem. 2017;44(3):948-966. doi: 10.1159/000485395. Epub 2017 Nov 27.
4
Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer.
Crit Rev Eukaryot Gene Expr. 2017;27(2):183-195. doi: 10.1615/CritRevEukaryotGeneExpr.2017019244.
5
Functions and Mechanisms of Long Noncoding RNAs in Ovarian Cancer.
Int J Gynecol Cancer. 2015 May;25(4):566-9. doi: 10.1097/IGC.0000000000000413.
6
Dysregulated Expression of Long Noncoding RNAs in Ovarian Cancer.
Int J Gynecol Cancer. 2016 Nov;26(9):1564-1570. doi: 10.1097/IGC.0000000000000828.
7
Long noncoding RNAs in head and neck cancer.
Oncotarget. 2017 Feb 7;8(6):10726-10740. doi: 10.18632/oncotarget.12960.
8
miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers.
Expert Rev Mol Diagn. 2018 Nov;18(11):963-979. doi: 10.1080/14737159.2018.1538794. Epub 2018 Oct 29.
9
Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
J Cell Physiol. 2018 Jun;233(6):5034-5043. doi: 10.1002/jcp.26369. Epub 2018 Jan 2.
10
Long non-coding RNAs in ovarian cancer.
J Exp Clin Cancer Res. 2018 Jun 19;37(1):120. doi: 10.1186/s13046-018-0793-4.
引用本文的文献
1
Natural Metabolites as Modulators of Sensing and Signaling Mechanisms: Unlocking Anti-Ovarian Cancer Potential.
Biomedicines. 2025 Jul 26;13(8):1830. doi: 10.3390/biomedicines13081830.
2
Regulation of Human Lung Adenocarcinoma Cell Proliferation by LncRNA AFAP-AS1 Through the miR-508/ZWINT Axis.
Int J Mol Sci. 2025 Jul 7;26(13):6532. doi: 10.3390/ijms26136532.
3
Deciphering the mysteries of MEG3 LncRNA and its implications in genitourinary cancers.
Front Oncol. 2025 Apr 2;15:1519103. doi: 10.3389/fonc.2025.1519103. eCollection 2025.
4
Senescence-Related LncRNAs: Pioneering Indicators for Ovarian Cancer Outcomes.
Phenomics. 2024 Sep 26;4(4):379-393. doi: 10.1007/s43657-024-00163-z. eCollection 2024 Aug.
5
Management of triple-negative breast cancer by natural compounds through different mechanistic pathways.
Front Genet. 2024 Jul 26;15:1440430. doi: 10.3389/fgene.2024.1440430. eCollection 2024.
6
Identification of long noncoding RNAs downregulated specifically in ovarian high-grade serous carcinoma.
Reprod Med Biol. 2024 Apr 3;23(1):e12572. doi: 10.1002/rmb2.12572. eCollection 2024 Jan-Dec.
7
Long Non-Coding RNAs: New Insights in Neurodegenerative Diseases.
Int J Mol Sci. 2024 Feb 14;25(4):2268. doi: 10.3390/ijms25042268.
8
Long noncoding RNA LINC00885 upregulates NCK1 to promote cell viability and migration of triple-negative breast cancer cells through sponging miR-654-3p.
Cancer Biomark. 2024;39(1):63-78. doi: 10.3233/CBM-230143.
9
Expression and Alteration Value of Long Noncoding RNA AB073614 and FER1L4 in Patients with Acute Myeloid Leukemia (AML).
Asian Pac J Cancer Prev. 2023 Jul 1;24(7):2271-2277. doi: 10.31557/APJCP.2023.24.7.2271.
10
Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis.
Int J Mol Sci. 2023 Jun 28;24(13):10798. doi: 10.3390/ijms241310798.
本文引用的文献
1
From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer.
Cancer Metastasis Rev. 2018 Mar;37(1):83-105. doi: 10.1007/s10555-017-9718-5.
2
LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.
Onco Targets Ther. 2017 Nov 10;10:5377-5390. doi: 10.2147/OTT.S147586. eCollection 2017.
3
Long Noncoding RNA MALAT1 Functions as a Sponge of MiR-200c in Ovarian Cancer.
Oncol Res. 2017 Sep 11. doi: 10.3727/096504017X15049198963076.
4
Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer.
Crit Rev Eukaryot Gene Expr. 2017;27(2):183-195. doi: 10.1615/CritRevEukaryotGeneExpr.2017019244.
5
LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway.
Eur Rev Med Pharmacol Sci. 2017 Jul;21(14):3176-3184.
6
Panel of seven long noncoding RNA as a candidate prognostic biomarker for ovarian cancer.
Onco Targets Ther. 2017 Jun 1;10:2805-2813. doi: 10.2147/OTT.S128797. eCollection 2017.
7
Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3.
Oncotarget. 2017 May 9;8(19):31714-31725. doi: 10.18632/oncotarget.15955.
8
Identification of a six-lncRNA signature associated with recurrence of ovarian cancer.
Sci Rep. 2017 Apr 7;7(1):752. doi: 10.1038/s41598-017-00763-y.
9
Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer.
Cancer Chemother Pharmacol. 2017 Mar;79(3):479-487. doi: 10.1007/s00280-017-3238-4. Epub 2017 Feb 8.
10
Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients.
Sci Rep. 2017 Feb 2;7(1):18. doi: 10.1038/s41598-017-00050-w.
Zotero 插件